Geode Capital Management LLC Has $9.77 Million Stock Holdings in Enfusion, Inc. (NYSE:ENFN)

Geode Capital Management LLC grew its stake in shares of Enfusion, Inc. (NYSE:ENFN) by 7.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,029,366 shares of the company’s stock after purchasing an additional 70,367 shares during the period. Geode Capital Management LLC owned approximately 0.80% of Enfusion worth $9,770,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. TenCore Partners LP bought a new position in Enfusion in the third quarter worth approximately $3,938,000. Dimensional Fund Advisors LP lifted its holdings in shares of Enfusion by 57.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock worth $4,466,000 after purchasing an additional 191,436 shares in the last quarter. Impax Asset Management Group plc lifted its holdings in shares of Enfusion by 25.4% in the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock worth $6,424,000 after purchasing an additional 136,948 shares in the last quarter. Scalar Gauge Management LLC grew its position in Enfusion by 21.8% in the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock valued at $5,227,000 after purchasing an additional 110,000 shares during the period. Finally, SG Americas Securities LLC bought a new stake in Enfusion during the 3rd quarter valued at $892,000. Institutional investors own 81.05% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on ENFN. Piper Sandler raised their price objective on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. Stifel Nicolaus raised their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.25.

Enfusion Price Performance

NYSE ENFN opened at $10.30 on Thursday. The company has a fifty day moving average price of $9.95 and a 200-day moving average price of $9.10. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of 257.56, a PEG ratio of 3.98 and a beta of 0.97. Enfusion, Inc. has a 1 year low of $7.52 and a 1 year high of $11.38.

Insider Buying and Selling

In other Enfusion news, CFO Bradley Herring sold 24,443 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $10.61, for a total value of $259,340.23. Following the transaction, the chief financial officer now owns 270,503 shares of the company’s stock, valued at approximately $2,870,036.83. The trade was a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the transaction, the chief operating officer now owns 1,143,544 shares of the company’s stock, valued at $11,469,746.32. This trade represents a 1.87 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,918 shares of company stock worth $484,037. 36.44% of the stock is owned by insiders.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.